Clinical Trial Update: PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion and posted results of Phase 1 and Phase 2 studies of PKC412 (midostaurin) in adults with acute myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• PKC412

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-07-17